Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study

Autor: Gunnar Gislason, Karl Emil Kristensen, John S. Markowitz, Henrik B. Rasmussen, Peter Riis Hansen, Xinwen Wang, Christian Torp-Pedersen, Hao Jie Zhu

Publikováno v: Kristensen, K E, Zhu, H J, Wang, X, Gislason, G H, Torp-Pedersen, C, Rasmussen, H B, Markowitz, J S & Hansen, P R 2014, ' Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study ', Clinical Pharmacology and Therapeutics, vol. 96, no. 6, pp. 713-722 . https://doi.org/10.1038/clpt.2014.183
Kristensen, K E, Zhu, H-J, Wang, X, Gislason, G H, Torp-Pedersen, C, Rasmussen, H B, Markowitz, J S & Hansen, P R 2014, ' Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction : A Proof-of-Concept Study ', Clinical Pharmacology and Therapeutics, vol. 96, no. 6, pp. 713–722 . https://doi.org/10.1038/clpt.2014.183

Clopidogrel is an oral antiplatelet prodrug, the majority of which is hydrolyzed to an inactive metabolite by hepatic carboxylesterase 1 (CES1). Most angiotensin-converting enzyme inhibitors (ACEIs) are also metabolized by this enzyme. We examined th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88209cd5d3e8aa956e1632c79d43217e
https://doi.org/10.1038/clpt.2014.183

Danish register-based study on the association between specific cardiovascular drugs and fragility fractures

Autor: Charlotte Andersson, Peter Weeke, Marie Sahlberg, Terese Sara Høj Jørgensen, Maia Torstensson, Jesper Ryg, Gunnar Gislason, Christian Torp-Pedersen, Karl Emil Kristensen, Annette Hansen, Katja Biering Leth-Møller, Ellen Holm

Publikováno v: Torstensson, M, Hansen, A H, Leth-Møller, K, Jørgensen, T S, Sahlberg, M I E, Andersson, C, Kristensen, K E, Ryg, J, Weeke, P, Torp-Pedersen, C, Gislason, G & Holm, E 2015, ' Danish register-based study on the association between specific cardiovascular drugs and fragility fractures ', BMJ Open, vol. 5, no. 12, e009522 . https://doi.org/10.1136/bmjopen-2015-009522
BMJ Open
Torstensson, M, Hansen, A H, Leth-Møller, K, Jørgensen, T S H, Sahlberg, M, Andersson, C, Kristensen, K E, Ryg, J, Weeke, P, Torp-Pedersen, C, Gislason, G & Holm, E 2015, ' Danish register-based study on the association between specific cardiovascular drugs and fragility fractures ', BMJ Open, vol. 5, no. 12, e009522 . https://doi.org/10.1136/bmjopen-2015-009522

OBJECTIVE: To determine whether drugs used in treatment of cardiovascular diseases (CVD-drugs), including hypertension, increase the risk of fragility fractures in individuals above the age of 65 years.DESIGN: Retrospective nationwide cohort study.SE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f14910f2abd1ea7f5b86d114f6387ebc
https://findresearcher.sdu.dk:8443/ws/files/129583440/Danish_register_based_study_on_the_association_between_specific_cardiovascular_drugs_and_fragility_fractures.pdf

[Genetic variability in the efficacy of clopidogrel]

Autor: Karl Emil, Kristensen, Henrik Berg, Rasmussen, Peter Riis, Hansen

Publikováno v: Ugeskrift for laeger. 175(11)

Hepatic cytochrome P450 (CYP) bioactivation of clopidogrel is reduced in subjects with the CYP2C19*2 loss-of-function allele. This allele has been linked to an increased risk of stent thrombosis after percutaneous coronary intervention. In contrast t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::91654ec95355ed9e713e36679cb9dc93
https://pubmed.ncbi.nlm.nih.gov/23480885

Increased bleeding risk without thromboembolic protection with antiplatelet treatment on top of oral anticoagulation in heart failure patients with atrial fibrillation and co-existing vascular disease

Autor: G. H. Gislason, Søren Lund Kristensen, Karl Emil Kristensen, Cengiz Özcan, Christian Torp-Pedersen, M. H. Ruwald, Morten Lock Hansen, Gyh Lip, Lars Køber, M. Lamberts

Publikováno v: Lamberts, M, Lip, G Y H, Ruwald, M H, Ozcan, C, Kristensen, K E, Kristensen, S L, Hansen, M L, Kober, L, Torp-Pedersen, C & Gislason, G H 2013, ' Increased bleeding risk without thromboembolic protection with antiplatelet treatment on top of oral anticoagulation in heart failure patients with atrial fibrillation and co-existing vascular disease ', European Heart Journal, vol. 34, no. Suppl. 1, 651, No. 3553 . https://doi.org/10.1093/eurheartj/eht309.3553

Purpose: Heart failure (HF), vascular disease and atrial fibrillation (AF) are all pathophysiological related and understanding antithrombotic therapy is crucial. Our aim was to investigate the impact of AF and antithrombotic therapy on prognosis in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3edc5013b14ad7fcf97f8a3dd83a339
https://vbn.aau.dk/da/publications/a2b952aa-cd59-4cae-8582-67dc56388847